Valid point. I was lazy but FDA could be swapped out for any other foreign regulatory agency.
My point was more that CEOs of large pharmaceutical companies aren’t going to partner at this stage. They either want to get in early and pay very little, or get in late and pay more when there’s no more risk.
Currently, in the middle of these late stage trials, the cost to partner or acquire Anavex is high but so is the risk. No CEO will jump into that risk/reward scenario with open arms.
News 
Market Data 
Discover 
